In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy

Lignende værker

• The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy
  af: Ehrhardt, Michael, et al.
  Udgivet: (2014)
• The FDA approved PI3K inhibitor GDC‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma
  af: Ehrhardt, Michael, et al.
  Udgivet: (2018)
• The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition
  af: Craveiro, Rogerio B, et al.
  Udgivet: (2017)
• Improved Glycemic Control With the Multi-Receptor Tyrosine Kinase Inhibitor Pazopanib
  af: Böhm, Steffen, et al.
  Udgivet: (2010)
• The Multi-targeted Kinase Inhibitor Pazopanib Causes Suppression and Regression of Choroidal Neovascularization
  af: Takahashi, Kyoichi, et al.
  Udgivet: (2009)